(1 - 7 von 11
)
ARGEN-X (EBR:ARGX) argenx to present complete data from the Phase 2...
www.webdisclosure.com
... from current therapies for managing IgG levels, including plasmapheresis, where benefit reversed more rapidly," commented Nicolas Leupin, CMO of argenx.
ArgenX reports hints to efficacy of ARGX-113 in generalised...
european-biotechnology.com
... evaluating in our two ongoing Phase II studies in immune thrombocytopenia and pemphigus vulgaris," said ArgenX's CMO Nicolas Leupin.
Argenx Starts Trial in Cutaneous T-cell Lymphoma Patients of ARGX-110
lymphomanewstoday.com
... cohort, resulting in several patients with partial response or stable disease,” Nicolas Leupin, CMO of argenx, said in a news release.
argenx reports interim data from first cohort of Phase 2 proof LSPvcwww.lspvc.com › news › argenx-reports-interim-dat...
www.lspvc.com
... control as characterized by the start of healing of existing lesions and absence of formation of new lesions," commented Nicolas Leupin, CMO of argenx.
sortiert nach Relevanz / Datum